Stifel Financial
MRVI icon

Stifel Financial’s Maravai LifeSciences MRVI Stock Holding History

Stifel Financial’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,027
Closed -$39.7K – 3775
2026
Q1 		$39.7K Buy
14,027
+3,000
+27% +$10.2K ﹤0.01% 3591
2025
Q4 		$35.8K Buy
+11,027
New +$37.1K ﹤0.01% 3542
2025
Q3 		– Sell
-11,399
Closed -$27.5K – 3603
2025
Q2 		$27.5K Buy
+11,399
New +$24K ﹤0.01% 3443
2023
Q4 		– Sell
-12,292
Closed -$123K – 3388
2023
Q3 		$123K Buy
12,292
+439
+4% +$4.82K ﹤0.01% 3078
2023
Q2 		$147K Buy
+11,853
New +$160K ﹤0.01% 3108
2021
Q4 		– Sell
-27,392
Closed -$1.34M – 3428
2021
Q3 		$1.34M Sell
27,392
-19,894
-42% -$970K ﹤0.01% 1861
2021
Q2 		$1.97M Buy
47,286
+35,986
+318% +$1.39M ﹤0.01% 1622
2021
Q1 		$403K Sell
11,300
-358
-3% -$11.9K ﹤0.01% 2609
2020
Q4 		$327K Buy
+11,658
New +$325K ﹤0.01% 2550

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Stifel Financial's MRVI Position: Q2 2026 in Review

Stifel Financial sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 14,027 shares — an estimated $39.7K sold.

Stifel Financial first reported a position in MRVI in Q4 2020 and held it in 9 quarters. The position peaked at $1.97M in Q2 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Stifel Financial reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
  • Stifel Financial sold 14,027 Maravai LifeSciences shares in Q2 2026, an estimated $39.7K.
  • Stifel Financial first reported a position in Maravai LifeSciences in Q4 2020 and held it in 9 quarters.
  • Stifel Financial's Maravai LifeSciences position peaked at $1.97M in Q2 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.